Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide injections require precise placement in subcutaneous tissue to ensure consistent absorption and minimize side effects. The FDA-approved locations for GLP-1 receptor agonist injections include the abdomen, thigh, and upper arm—each offering distinct advantages for patient comfort and medication efficacy. Understanding proper injection site selection and rotation patterns is essential for long-term treatment success.
Approved Semaglutide Injection Sites for Safe Administration
Semaglutide and other GLP-1 medications are designed for subcutaneous injection into specific body regions with adequate fatty tissue. The three primary FDA-approved injection sites are the lower abdomen (at least 2 inches from the navel), the outer thigh, and the back of the upper arm. Each location provides reliable subcutaneous access and allows for proper medication distribution into the bloodstream over time.
The abdomen is the most commonly chosen site because it offers consistent absorption rates and large surface area for site rotation. The thigh and upper arm work equally well for subcutaneous delivery but may have slightly slower absorption profiles. Most patients find abdominal injections most convenient since they can be self-administered without assistance or awkward positioning.
Why Gluteal Injections Are Not Recommended for GLP-1 Therapy
The buttock region contains primarily muscle tissue with thinner subcutaneous fat layers compared to the abdomen and thigh. Injecting into muscle instead of subcutaneous tissue (intramuscular injection) can cause significantly different absorption rates and unpredictable medication levels in the blood. This inconsistency may lead to reduced effectiveness or unexpected side effects during your treatment cycle.
Intramuscular injections of GLP-1 drugs also carry higher risks of tissue damage and prolonged soreness compared to approved subcutaneous sites. Medical guidelines specifically designate subcutaneous-only administration for semaglutide because the medication's pharmacokinetics depend on slow diffusion through fatty tissue. Deviating from these established protocols may compromise your treatment outcomes and patient safety.
Best Practices for Rotating Your Injection Sites
Site rotation is essential for preventing lipodystrophy—a condition where repeated injections in the same location cause fat tissue to thicken or deteriorate. PlexusDx recommends rotating between different body regions each week and varying injection spots within each region by at least one inch. For example, inject in the left abdomen one week, right abdomen the next, then alternate to thigh and upper arm in subsequent weeks.
Proper rotation maintains consistent medication absorption, reduces local irritation, and prevents long-term tissue changes that could affect future injections. Patients should mark injection sites mentally or use a small calendar to track location patterns. This systematic approach ensures maximum therapeutic benefit from your compounded semaglutide throughout your weight loss journey.
How PlexusDx Supports Safe and Effective GLP-1 Injection Therapy
PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies at affordable, flat-rate pricing starting at $149 per month—with no flat per-compound pricing increases as your treatment progresses. Each prescription includes detailed injection instructions, sterile supplies, and access to clinical support for questions about proper administration technique. PlexusDx serves all 50 states without requiring insurance, making personalized GLP-1 therapy accessible to everyone.
Patients who want to optimize their medication selection based on genetic factors can add the Precision Peptide Genetic Test for $99 after their first month of treatment. This assessment analyzes how your body responds to GLP-1 compounds by examining key genetic variants in your peptide pathways. PlexusDx uses these insights to match you with semaglutide, tirzepatide, or combination therapies that align with your individual biology and weight loss goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I inject semaglutide into my buttocks instead of my abdomen?
No—buttock injections are not recommended because this region contains primarily muscle tissue rather than subcutaneous fat. GLP-1 injections require subcutaneous delivery to ensure proper absorption and medication effectiveness. Stick with approved sites: abdomen, outer thigh, or upper arm.
What happens if I inject semaglutide into muscle instead of fat?
Intramuscular injection causes unpredictable absorption rates, inconsistent blood levels, and increased risk of local tissue damage and pain. Your medication may work less effectively, and you might experience unexpected side effects or poor weight loss results. Always inject into subcutaneous fatty tissue as directed by your healthcare provider.
How often should I rotate my semaglutide injection sites?
Rotate to a different body region each week and vary injection spots within each region by at least one inch. This prevents lipodystrophy and maintains consistent medication absorption. For example: left abdomen week 1, right abdomen week 2, left thigh week 3, right arm week 4.
Does PlexusDx charge more for higher semaglutide doses?
No—PlexusDx charges a flat rate starting at $149 per month for compounded semaglutide injections regardless of your dose level. Your dose may need to go up, but your price won't. This transparent pricing applies across all three commitment tiers.
Can genetic testing help me choose the right GLP-1 medication?
Yes—PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month) that analyzes 14 pathways and 49 peptides to identify how your body responds to semaglutide, tirzepatide, and other GLP-1 compounds. Key variants like GLP1R rs6923761 and GIPR rs1800437 predict individual medication responsiveness.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Weight Loss: Does Ozempic Work for Emotional Eaters?
Wegovy Prior Authorization: Understanding Approval Timelines